{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:33:00Z","timestamp":1787776380056,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study investigated the efficacy of adding the oral N-acetyl cysteine (NAC) supplement to the cystic fibrosis (CF) treatment regimen compared to adding a placebo. It also studied the quality of life and respiratory indicators of patients aged 6\u201318 with mild-to-moderate pulmonary involvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This clinical trial was a randomized, quasi-experimental pilot and add-on therapy controlled with a placebo for 3 months. The case group received 200 mg of oral NAC three times a day. In contrast, the control group had a placebo in the same way. From the 2021 fall to the summer of 2022, 38 CF patients referred to Imam Hossein Children\u2019s Hospital Clinic were finally examined. They were clinically stable with a forced expiratory volume in the first second (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) level of more than 50% and no history of underlying cardiovascular and renal diseases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>The differences between the groups were not significant. In the placebo group, key measures remained unchanged, whereas the NAC group had an improvement in the CF Questionnaire-Revised score but no notable changes in other indices. Overall, comparisons of forced vital capacity (FVC) between the groups showed no variation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      The indicators of FEV\n                      <jats:sub>1<\/jats:sub>\n                      , FVC, FEV\n                      <jats:sub>1<\/jats:sub>\n                      \/FVC,\n                      <jats:italic toggle=\"yes\">forced expiratory flow between 25% and 75% of vital capacity<\/jats:italic>\n                      , and the quality of life of the case group were not significantly different from those of the placebo group, and no significant differences were observed between this medicine and placebo.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrpp.jrpp_54_24","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T06:00:41Z","timestamp":1741672841000},"page":"72-77","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Adding Oral N acetyl Cysteine Supplement to the Cystic Fibrosis Treatment Regimen: A Randomized Quasi-Experimental Trial"],"prefix":"10.4103","volume":"13","author":[{"given":"Sedigheh","family":"Keshavarz","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Reisi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonology, Imam Hossein Children\u2019s Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Keivanfar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonology, Imam Hossein Children\u2019s Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Rabbani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Mohammad","family":"Sabzghabaee","sequence":"additional","affiliation":[{"name":"Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"R1-20250311","doi-asserted-by":"crossref","first-page":"608821","DOI":"10.3389\/fped.2020.608821","article-title":"Early diagnosis and intervention in cystic fibrosis: Imagining the unimaginable","volume":"8","author":"Coverstone","year":"2020","journal-title":"Front Pediatr"},{"key":"R2-20250311","doi-asserted-by":"crossref","first-page":"104169","DOI":"10.1016\/j.lpm.2023.104169","article-title":"Cystic fibrosis","volume":"52","author":"Fajac","year":"2023","journal-title":"Presse Med"},{"key":"R3-20250311","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.medcli.2023.06.006","article-title":"Cystic fibrosis: Epidemiology, clinical manifestations, diagnosis and treatment","volume":"161","author":"Diab C\u00e1ceres","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"R4-20250311","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic pathogens in cystic fibrosis: Epidemiology and pathogenesis of lung infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R6-20250311","first-page":"CD007020","article-title":"Antioxidant supplementation for lung disease in cystic fibrosis","volume":"10","author":"Ciofu","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20250311","first-page":"33","article-title":"First cystic fibrosis patient registry annual data report-cystic fibrosis foundation of Iran","volume":"57","author":"Aghamohammadi","year":"2019","journal-title":"Acta Med Iran"},{"key":"R8-20250311","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: Randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R9-20250311","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ppul.24524","article-title":"Efficacy and safety of oral sildenafil in cystic fibrosis children with mild to moderate lung disease","volume":"55","author":"Reisi","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"R10-20250311","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jcf.2020.02.017","article-title":"Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis","volume":"19","author":"Perrem","year":"2020","journal-title":"J Cyst Fibros"},{"key":"R11-20250311","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002809502900501","article-title":"Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis","volume":"29","author":"Oster","year":"1995","journal-title":"Ann Pharmacother"},{"key":"R12-20250311","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-017-0592-z","article-title":"Electronic applications for the CFQ-R scoring","volume":"18","author":"Ronit","year":"2017","journal-title":"Respir Res"},{"key":"R13-20250311","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1164\/rccm.200307-959OC","article-title":"Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis","volume":"169","author":"Paul","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-20250311","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0140-6736(93)92297-7","article-title":"Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis","volume":"342","author":"Ranasinha","year":"1993","journal-title":"Lancet"},{"key":"R15-20250311","first-page":"CD007923","article-title":"Timing of dornase alfa inhalation for cystic fibrosis","volume":"3","author":"Dentice","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250311","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"J Pediatr"},{"key":"R17-20250311","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jama.1992.03480140073036","article-title":"Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study","volume":"267","author":"Aitken","year":"1992","journal-title":"JAMA"},{"key":"R18-20250311","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM199203193261207","article-title":"A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis","volume":"326","author":"Hubbard","year":"1992","journal-title":"N Engl J Med"},{"key":"R19-20250311","first-page":"CD007168","article-title":"Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis","volume":"2013","author":"Tam","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R20-20250311","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1183\/09031936.93.02030234","article-title":"N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: Clinical score, spirometry and ciliary motility","volume":"2","author":"Stafanger","year":"1989","journal-title":"Eur Respir J"},{"key":"R21-20250311","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/030006059502300409","article-title":"The management of cystic fibrosis with carbocysteine lysine salt: Single-blind comparative study with ambroxol hydrochloride","volume":"23","author":"Caramia","year":"1995","journal-title":"J Int Med Res"},{"key":"R22-20250311","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/014107689809100705","article-title":"Targeting of dornase alpha therapy in adult cystic fibrosis","volume":"91","author":"Ledson","year":"1998","journal-title":"J R Soc Med"},{"key":"R23-20250311","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1542\/peds.2005-0308","article-title":"A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis","volume":"116","author":"Fitzgerald","year":"2005","journal-title":"Pediatrics"},{"key":"R24-20250311","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ppul.22800","article-title":"Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial","volume":"49","author":"Bakker","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"R25-20250311","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00441781","article-title":"A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis","volume":"144","author":"Ratjen","year":"1985","journal-title":"Eur J Pediatr"},{"key":"R26-20250311","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.1999.tb01265.x","article-title":"Systematic review of N-acetylcysteine in cystic fibrosis","volume":"88","author":"Duijvestijn","year":"1999","journal-title":"Acta Paediatr"},{"key":"R27-20250311","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcf.2014.09.015","article-title":"The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection \u2013 A pilot study","volume":"14","author":"Skov","year":"2015","journal-title":"J Cyst Fibros"},{"key":"R28-20250311","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial","volume":"14","author":"Conrad","year":"2015","journal-title":"J Cyst Fibros"},{"key":"R29-20250311","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1164\/ajrccm\/148.1.145","article-title":"Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis","volume":"148","author":"Ramsey","year":"1993","journal-title":"Am Rev Respir Dis"}],"container-title":["Journal of Research in Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_54_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:09:44Z","timestamp":1787774984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrpp.jrpp_54_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jrpp.jrpp_54_24","relation":{},"ISSN":["2319-9644","2279-042X"],"issn-type":[{"value":"2319-9644","type":"print"},{"value":"2279-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-04-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}